سعر موتينورم 5 مجم/5 مل معلق 125 مل 2024

Domperidone oral suspension 5 mg/5 ml (1 mg/ml), 125 ml bottle (GSK Motinorm).

• Relief of nausea and vomiting; symptoms of delayed gastric emptying / dyspepsia where a dopamine antagonist prokinetic is indicated (per Motilium-class labeling).Population: Adults as labeled; pediatric use restricted in many jurisdictionsMHRA / EU Motilium-class product information (domperidone)

• Common: dry mouth. Uncommon/rare: extrapyramidal symptoms, galactorrhoea, gynaecomastia, amenorrhoea; serious: QT prolongation, torsades de pointes.General active-ingredient information · MHRA / EU Motilium-class product information (domperidone)

• Known hypersensitivity to domperidone; prolactin-releasing pituitary tumour; concomitant potent CYP3A4 inhibitors; conditions where cardiac conduction/QT prolongation is a concern (including significant electrolyte disturbances); GI haemorrhage, obstruction or perforation.General active-ingredient information · MHRA / EU Motilium-class product information (domperidone)

• Domperidone prolongs QT and has been associated with serious ventricular arrhythmias and sudden cardiac death; use lowest effective dose for shortest duration; avoid in patients >60 years when possible; ECG if cardiac risk factors.General active-ingredient information · MHRA / EU Motilium-class product information (domperidone)

• Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin, ritonavir)MajorIncreased domperidone exposure and QT risk; combination contraindicated in Motilium-class labeling. Management: Do not co-administer.MHRA / EU Motilium-class product information (domperidone)

• Domperidone: use in pregnancy only if clearly necessary; excreted in breast milk — avoid during lactation unless benefit outweighs risk (per EU Motilium-class labeling).General active-ingredient information · MHRA / EU Motilium-class product information (domperidone)

• Domperidone: Blocks peripheral D2 receptors in the chemoreceptor trigger zone and GI tract; limited CNS penetration.